Autolus Therapeutics Plc ADR (AUTL)

$2.44 -0.05 (-2.01%)
Market Cap 705.27M
Revenue (ttm) 10.12M
Net Income (ttm) -220.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,180.43%
Debt to Equity Ratio 0.00
Volume 952,600
Avg Vol 2,234,924
Day's Range N/A - N/A
Shares Out 266.14M
Stochastic %K 56%
Beta 1.81
Analysts Strong Sell
Price Target $9.84

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3829 6230
Address:
The Mediaworks, 191 Wood Lane White City, London, United Kingdom
gandolf63
gandolf63 Jul. 16 at 6:38 PM
$AUTL Next catalyst ”Autolus expects potential marketing approvals from the MHRA and EMA in the second half of 2025. ”
0 · Reply
lola269
lola269 Jul. 16 at 12:48 PM
$IOVA we did great yesterday,let's stay strong today too. Another block placed $ACRV still alone $CCCC C(ure) C(ancer) C(ash) C(oke) in that order $ATYR 6 by Friday $AUTL still good Lfg!
1 · Reply
TricksterT
TricksterT Jul. 15 at 9:38 PM
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — TradingView News $AUTL https://www.tradingview.com/news/reuters.com,2025-07-15:newsml_GNX5lhk6W:0-autolus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
1 · Reply
gandolf63
gandolf63 Jul. 15 at 9:30 PM
$AUTL
0 · Reply
gandolf63
gandolf63 Jul. 15 at 8:50 PM
$AUTL we had to take a breather pullback and consilidate next move up in a couple of days imo
0 · Reply
lola269
lola269 Jul. 15 at 3:11 PM
Today is biotech shorting day Henceforth today is buy day Look at all of them..down on no news or good news Added today mates LFG! $IOVA $ACRV $AUTL $CCCC $ATYR
1 · Reply
Mancunian
Mancunian Jul. 15 at 2:39 PM
$AUTL No particular news but I suspect that the company is trading very well which should be confirmed shortly.
1 · Reply
TricksterT
TricksterT Jul. 15 at 2:22 PM
$AUTL shorts be mad. They are trying to cover but it’s not happening for cheap.
1 · Reply
Holy_Xerxes
Holy_Xerxes Jul. 15 at 2:10 PM
$AUTL why? Any specific news this is being sold off?
1 · Reply
Trending__Now
Trending__Now Jul. 15 at 9:42 AM
$AUTL Institutional ownership growing, along with short interest. July/Sept trial update. Medicare/Medicaid codes live in April with EU launch later this year. Projections are a 51% annual growth rate over the next 3 years. Accumulate and sell 3 years from now? Take the win and move on.
1 · Reply
Latest News on AUTL
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 15, 2025, 4:05 PM EDT - 1 day ago

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Jun 12, 2025, 2:00 AM EDT - 4 weeks ago

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market

Jun 6, 2025, 11:09 AM EDT - 5 weeks ago

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market

Autolus Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025, 4:05 PM EDT - 6 weeks ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 23, 2025, 8:30 AM EDT - 7 weeks ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

I Missed The Quantum Rally - I Won't Miss The Next One

May 20, 2025, 5:47 AM EDT - 2 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC CAPR CLPT EDIT NTLA VANI VERV

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 14, 2025, 9:30 AM EDT - 2 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

May 11, 2025, 4:22 AM EDT - 2 months ago

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 8, 2025, 7:00 AM EDT - 2 months ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 25, 2025, 12:06 PM EDT - 2 months ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 23, 2025, 4:05 PM EDT - 3 months ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 22, 2025, 7:00 AM EDT - 3 months ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 7:00 AM EDT - 3 months ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Apr 1, 2025, 7:00 AM EDT - 3 months ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 11:55 AM EDT - 4 months ago

Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 20, 2025, 7:00 AM EDT - 4 months ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Mar 6, 2025, 7:00 AM EST - 4 months ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

Mar 4, 2025, 10:21 AM EST - 4 months ago

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Jan 17, 2025, 7:00 AM EST - 6 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Dec 9, 2024, 7:30 PM EST - 7 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 21, 2024, 12:16 AM EST - 8 months ago

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 2:57 PM EST - 8 months ago

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Nov 8, 2024, 4:23 PM EST - 8 months ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 28, 2024, 5:00 PM EDT - 9 months ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Sep 6, 2024, 2:12 PM EDT - 11 months ago

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 12:05 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

May 31, 2024, 8:00 AM EDT - 1 year ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript

May 17, 2024, 12:55 PM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 17, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

May 14, 2024, 1:02 PM EDT - 1 year ago

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Apr 24, 2024, 10:00 AM EDT - 1 year ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Autolus Therapeutics Announces Changes to its Board of Directors

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Announces Changes to its Board of Directors

Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript

Mar 15, 2024, 5:23 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Mar 12, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Feb 29, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Autolus Announces Pricing of Underwritten Offering

Feb 8, 2024, 7:00 AM EST - 1 year ago

Autolus Announces Pricing of Underwritten Offering

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Feb 8, 2024, 5:45 AM EST - 1 year ago

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Autolus Upgrades Leadership And Faces CAR-T Approval

Feb 6, 2024, 9:52 AM EST - 1 year ago

Autolus Upgrades Leadership And Faces CAR-T Approval

Autolus Therapeutics announces publication in ACS Chemical Biology

Jan 23, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics announces publication in ACS Chemical Biology

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

Jan 22, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast

Dec 18, 2023, 4:12 AM EST - 1 year ago

Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

Dec 9, 2023, 8:30 PM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

Nov 27, 2023, 7:00 AM EST - 1 year ago

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

Nov 15, 2023, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

Autolus Therapeutics announces participation in upcoming conferences

Nov 6, 2023, 7:00 AM EST - 1 year ago

Autolus Therapeutics announces participation in upcoming conferences

Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Call Transcript

Nov 3, 2023, 10:05 PM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Call Transcript

gandolf63
gandolf63 Jul. 16 at 6:38 PM
$AUTL Next catalyst ”Autolus expects potential marketing approvals from the MHRA and EMA in the second half of 2025. ”
0 · Reply
lola269
lola269 Jul. 16 at 12:48 PM
$IOVA we did great yesterday,let's stay strong today too. Another block placed $ACRV still alone $CCCC C(ure) C(ancer) C(ash) C(oke) in that order $ATYR 6 by Friday $AUTL still good Lfg!
1 · Reply
TricksterT
TricksterT Jul. 15 at 9:38 PM
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — TradingView News $AUTL https://www.tradingview.com/news/reuters.com,2025-07-15:newsml_GNX5lhk6W:0-autolus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
1 · Reply
gandolf63
gandolf63 Jul. 15 at 9:30 PM
$AUTL
0 · Reply
gandolf63
gandolf63 Jul. 15 at 8:50 PM
$AUTL we had to take a breather pullback and consilidate next move up in a couple of days imo
0 · Reply
lola269
lola269 Jul. 15 at 3:11 PM
Today is biotech shorting day Henceforth today is buy day Look at all of them..down on no news or good news Added today mates LFG! $IOVA $ACRV $AUTL $CCCC $ATYR
1 · Reply
Mancunian
Mancunian Jul. 15 at 2:39 PM
$AUTL No particular news but I suspect that the company is trading very well which should be confirmed shortly.
1 · Reply
TricksterT
TricksterT Jul. 15 at 2:22 PM
$AUTL shorts be mad. They are trying to cover but it’s not happening for cheap.
1 · Reply
Holy_Xerxes
Holy_Xerxes Jul. 15 at 2:10 PM
$AUTL why? Any specific news this is being sold off?
1 · Reply
Trending__Now
Trending__Now Jul. 15 at 9:42 AM
$AUTL Institutional ownership growing, along with short interest. July/Sept trial update. Medicare/Medicaid codes live in April with EU launch later this year. Projections are a 51% annual growth rate over the next 3 years. Accumulate and sell 3 years from now? Take the win and move on.
1 · Reply
RonIsWrong
RonIsWrong Jul. 14 at 7:00 PM
$AUTL and it was. textbook.
2 · Reply
Gugger
Gugger Jul. 14 at 5:20 PM
$AUTL Hey shorts u better cover now, this will be a nightmare to cover 14 Mio. shares ... 💩😥
2 · Reply
RonIsWrong
RonIsWrong Jul. 14 at 5:16 PM
$AUTL solid!
0 · Reply
lob11
lob11 Jul. 14 at 5:11 PM
$AUTL Keep it up
0 · Reply
keypatience
keypatience Jul. 14 at 4:24 PM
$AUTL
0 · Reply
lola269
lola269 Jul. 14 at 12:31 PM
$IOVA great news! If the pump gets neutralized don't sweat it This is a castle of blocks and each block is heavier than the last $ACRV can someone invest 10$ and a chocolate bar in this? I feel very alone in the board $ATYR waiting for the sun $AUTL same $CCCC it's good after all ,still time to catch the bull run LFG Don't
1 · Reply
TricksterT
TricksterT Jul. 14 at 12:25 PM
$AUTL nice work we went from bearish to extremely bullish in a few days. Should be a fun 3 weeks upcoming.
0 · Reply
Ah222222
Ah222222 Jul. 12 at 8:36 PM
$AUTL
0 · Reply
monoksop
monoksop Jul. 12 at 12:16 PM
$AUTL Something something from the impatient to the patient.
0 · Reply
Axchange08
Axchange08 Jul. 12 at 2:52 AM
$AUTL im all in baby
0 · Reply
RonIsWrong
RonIsWrong Jul. 11 at 7:17 PM
$AUTL
1 · Reply
lola269
lola269 Jul. 11 at 1:41 PM
I reiterate LFG! $ACRV no retail interest, prove me wrong $AUTL just a good company $ATYR three months left $CCCC I have no God damn clue $IOVA just don't sell when they try to scare you
2 · Reply